Lorraine Tosiello
Internal Medicine · Asbury Park, NJNPI 1659350171
Payments from drug & device makers
Across 213 payments — averaging $21.17 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Viiv Healthcare Company$2K
- Gilead$1K
- Merck$291
- Johnson & Johnson$221
- Theratechnologies Inc.$193
- Janssen Products, LP$189
- plus $397 from 8 others
What the payments were for
- Consulting fees$46010%
- Food & beverage$3,79584%
- Education$2546%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Viiv Healthcare Company | 93 | $2,200 |
| Gilead | 54 | $1,017 |
| Merck | 20 | $291 |
| Johnson & Johnson(2 entities) | 15 | $221 |
| Theratechnologies Inc. | 8 | $193 |
| Janssen Products, LP | 2 | $189 |
| GSK | 5 | $125 |
| AbbVie(2 entities) | 4 | $79 |
| Napo Pharmaceuticals Inc | 3 | $49 |
| Sanofi Pasteur Inc. | 2 | $38 |
| Phadia US Inc. | 2 | $37 |
| Antares Pharma, Inc. | 2 | $29 |
| EMD Serono, Inc. | 2 | $26 |
| Alkermes, Inc. | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- DOVATO$710
How this compares
$4,509 in reported general payments places this provider in the 85th percentile of 4,032 internal medicine providers in New Jersey.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| DovatoDolutegravir Sodium/Lamivudine | 134 | $384,571 |
| BiktarvyBictegrav/Emtricit/Tenofov Ala | 97 | $383,190 |
| TivicayDolutegravir Sodium | 88 | $231,989 |
| RukobiaFostemsavir Tromethamine | 19 | $161,960 |
| JulucaDolutegravir/Rilpivirine | 39 | $123,837 |
| PifeltroDoravirine | 67 | $112,200 |
| DescovyEmtricitabine/Tenofov Alafenam | 47 | $95,287 |
| OzempicSemaglutide | 33 | $33,531 |
| MytesiCrofelemer | 11 | $27,971 |
| FarxigaDapagliflozin Propanediol | 42 | $26,254 |
| JardianceEmpagliflozin | 26 | $15,399 |
| Maraviroc | 12 | $12,166 |
| EliquisApixaban | 22 | $11,548 |
| Breo ElliptaFluticasone/Vilanterol | 24 | $9,136 |
| Etravirine | 11 | $7,959 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Viiv Healthcare CompanyDovato, Tivicay, Rukobia, Juluca | $2,200 | $902,357280 claims |
| GileadBiktarvy, Descovy | $1,017 | $478,477144 claims |
| MerckPifeltro | $291 | $112,20067 claims |
| Napo Pharmaceuticals IncMytesi | $49 | $27,97111 claims |
| GSKBreo Ellipta, Arnuity Ellipta | $125 | $11,11035 claims |
| AbbVieRestasis Multidose | $79 | $6,69111 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 4,032 internal medicine providers in New Jersey.
Other internal medicine in Asbury Park
- Sanjiv SharmaToms River$33.9M
- Jeffrey CarsonNew Brunswick$13.8M
- Samer HaddadHamilton$6.8M
- Magdy ShenoudaWall$3.7M
- Samar HameedLivingston$3.6M
- Jane RohlfTrenton$2.7M
- Mohammed NisarEdison$2.6M
- Michael CasserNew Milford$2.2M
- Sumitha ReddyHamilton$2M
- Helio PedroNewark$1.8M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.